About Tegsedi
For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

About Tegsedi

For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

About hATTR
Mode of Action
Read more
Mode of Action

Mode of Action

Tegsedi targets TTR production in hATTR1,2

Read more
Efficacy

Efficacy

Tegsedi significantly delay disease progression vs placebo1

Read more
Safety

Safety

Up to 6 years of experience in clinical trials and over 220 patients years3

Read more
Administration

Administration

Tegsedi is administered as a convenient weekly subcutaneous injection1,2

Read more
About hATTR

About hATTR

Hereditary transthyretin amyloidosis is a rapidly progressive and life-shortening disease

Read more
Tegsedi CONNECT

Tegsedi CONNECT

Empowering independence for people living with hATTR

Read more
References

mRNA, messenger ribonucleic acid; TTR, transthyretin.
OLE, open-label extension; TTR, transthyretin

  1. Tegsedi Summary of Product Characteristics. April 2021.
  2. Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.
  3. Coelho T et al. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis. OPR15, 7th Congress of the European Academy of Neurology 2021, 19-22 June 20.